Journal of Lipid and Atherosclerosis · Published 2026-01-01 · DOI 10.12997/jla.2026.15.2.361
Objective We aimed to investigate the efficacy and safety of a combination of fimasartan 30 mg and moderate-intensity statins in patients with hypertension and dyslipidemia in a real-world setting. Methods This non-interventional, multicenter, prospective observational study included 5,264 patients receiving a combination of fimasartan 30 mg and moderate-intensity statins with 12-week follow-up data. Co-primary efficacy outcomes were the percentage of patients that achieved target blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) control. Safety outcomes included adverse drug reactions and treatment-emergent adverse events. Results At 12 weeks, the proportion of patients individually achieving target BP and LDL-C was 74.4% (95% confidence interval [CI], 73.2–75.5) and 85.6% (95% CI, 84.5–86.8), respectively. The proportion of patients achieving simultaneous control of target BP and LDL-C was 65.6% (95% CI, 64.1–67.2). The median (interquartile range; IQR) differences in systolic and diastolic BPs from baseline to 12 weeks were −8.0 mmHg (−19.0 to 0.0) and −4.0 mmHg (−11.0 to 0.0), respectively (both p-values <0.0001). The median (IQR) percentage change in LDL-C from baseline to 12 weeks was −11.5% (−33.5 to 4.8) (p<0.0001). No significant adverse drug reactions or serious treatment-emergent adverse events were reported during the study period. Conclusion Findings of this study demonstrate that a combination of fimasartan 30 mg and moderate-intensity statins results in excellent control of BP and LDL-C levels without any safety issues.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →